The latest round of bidding for the generic drug business of Germany's Merck KGaA pushed offers over the €4 billion ($5.4 billion) mark, according to a report in the Financial Times. Four bidding groups are still in the competition: Teva, Mylan, Actavis and a pair of private equity firms--Apax Partners and Bain Capital. Merck officials said as late as last Friday that no final decision on a sale had been made and the amount of financial information being made available to would-be buyers is still limited. Another round of bidding may be forthcoming.
- read the AFX report on the bidding